الفهرس 
Post transplantation cyclophosphamide to prevent graft-versus-host-disease in allogeneic peripheral blood hematopoietic stem cell transplantation from HLA-matched donors
ContentsOnly 14 pages are availabe for public view
 |  | from | 172 |  |  |
| | | from | 172 | | |
Abstract
Background: GVHD prophylaxis with Calcineurin inhibitor (CNI) and methotrexate (MTX) has been considered the standard of care. Trial initially evaluating Post-transplant Cyclophosphamide (PT-Cy) with or without immunosuppressive agents (IS) in Haploidentical donors have shown promising results. While, its use in HLA-matched donors and comparing it to conventional prophylaxis is less explored. Objective: The aim of this study is to identify the impact of post transplantation cyclophosphamide in HLA matched sibling donors receiving PBSCT on the rates of GVHD, OS, NRM, DFS and relapse compared to conventional prophylaxis. Patients and methods: 150 patients having malignant hematological disorders undergoing PBSCT with matched sibling donors (MSD) receiving different GVHD prophylaxis to compare the incidence of chronic GVHD. group A included 75 who were studied prospectively receiving post-transplantation Cyclophosphamide as a GVHD prophylaxis given at a dose of 50 mg/kg/day on days 3 and 4 post-transplantation, and cyclosporine (CSA) starting day 5. Patients were treated at 2 transplant centers during the period from December 2017 to June 2019. Pre-transplant conditioning regimen was fludarabine and busulfan (FLU/BU) given to all of the patients. group B included 75 closely matched patients in which there data were retrospectively collected from the same transplant center. Patients received conventional GVHD prophylaxis with CNI and methotrexate (15 mg/m2 IV day +1, 10 mg/m2 day +3,+6, +11) during the period from September 2015 to August 2019. Pre-transplant conditioning regimens were Bu/Cy (64 %), Flu/Bu (24%) and TBI/Cy (12 %)